| 2025年中报 | 2024年年报 | 2024年中报 | |
|---|---|---|---|
| 营业收入(元) | |||
| CRO服务(元) | 99,737,469.52 | 168,526,230.05 | 88,344,706.53 |
| 房屋租赁(元) | 14,137,201.74 | 26,380,914.64 | 13,696,680.31 |
| 基因(元) | 4,821,358.94 | 8,553,807.22 | 4,855,486.63 |
| 抗体(元) | 44,383,113.38 | 106,492,689.82 | 52,036,491.77 |
| 培养基(元) | 13,484,161.35 | 28,226,002.54 | 13,300,423.26 |
| 重组蛋白(元) | 146,143,315.15 | 273,114,403.87 | 132,757,298.11 |
| 其他(元) | 1,748,554.71 | 2,377,468.91 | 669,871.16 |
| 营业成本(元) | |||
| CRO服务(元) | 47,652,837.66 | 88,340,000.88 | 45,404,360.94 |
| 房屋租赁(元) | 3,613,808.45 | 6,783,675.60 | 3,536,669.10 |
| 基因(元) | 174,299.69 | - | 601,934.63 |
| 抗体(元) | 4,029,013.13 | 11,979,477.01 | 7,103,848.53 |
| 培养基(元) | 5,811,065.44 | - | 5,193,857.28 |
| 重组蛋白(元) | 21,756,355.96 | 42,119,660.87 | 18,548,998.11 |
| 其他(元) | 1,310,333.97 | - | 593,074.32 |
| 毛利(元) | |||
| CRO服务(元) | 52,084,631.86 | 80,186,229.17 | 42,940,345.59 |
| 房屋租赁(元) | 10,523,393.29 | 19,597,239.04 | 10,160,011.21 |
| 基因(元) | 4,647,059.25 | - | 4,253,552.00 |
| 抗体(元) | 40,354,100.25 | 94,513,212.81 | 44,932,643.24 |
| 培养基(元) | 7,673,095.91 | - | 8,106,565.98 |
| 重组蛋白(元) | 124,386,959.19 | 230,994,743.00 | 114,208,300.00 |
| 其他(元) | 438,220.74 | - | 76,796.84 |
| 毛利率(%) | |||
| CRO服务(%) | 52.22 | 47.58 | 48.61 |
| 房屋租赁(%) | 74.44 | 74.29 | 74.18 |
| 基因(%) | 96.38 | - | 87.60 |
| 抗体(%) | 90.92 | 88.75 | 86.35 |
| 培养基(%) | 56.90 | - | 60.95 |
| 重组蛋白(%) | 85.11 | 84.58 | 86.03 |
| 其他(%) | 25.06 | - | 11.46 |
| 收入构成(%) | |||
| CRO服务(%) | 30.74 | 27.46 | 28.90 |
| 房屋租赁(%) | 4.36 | 4.30 | 4.48 |
| 基因(%) | 1.49 | 1.39 | 1.59 |
| 抗体(%) | 13.68 | 17.35 | 17.02 |
| 培养基(%) | 4.16 | 4.60 | 4.35 |
| 重组蛋白(%) | 45.04 | 44.50 | 43.43 |
| 其他(%) | 0.54 | 0.39 | 0.22 |
| 毛利构成(%) | |||
| CRO服务(%) | 21.69 | 18.85 | 19.11 |
| 房屋租赁(%) | 4.38 | 4.61 | 4.52 |
| 基因(%) | 1.94 | 0.00 | 1.89 |
| 抗体(%) | 16.81 | 22.22 | 20.00 |
| 培养基(%) | 3.20 | 0.00 | 3.61 |
| 重组蛋白(%) | 51.80 | 54.31 | 50.83 |
| 其他(%) | 0.18 | 0.00 | 0.03 |